The Tech That Drives Business Innovation: Lenovo and DreamWorks
27.5.2025 15:00:00 CEST | Business Wire | Press Release
DreamWorks Animation is deepening its collaboration with Lenovo, naming the company its preferred compute services, workstation, and solutions provider. This marks a milestone in a trusted partnership now strengthened by Lenovo’s solutions and services. By bringing together devices, data center infrastructure, and services into a seamless Lenovo ecosystem, DreamWorks has the compute power to scale with the ever-growing demands of its artistic and technical teams -- an essential advantage in an increasingly dynamic landscape. At the core of this collaboration is a shared commitment to service excellence, ensuring DreamWorks remains supported through every business transformation.
Lenovo’s strategic services and solutions have already delivered a quantifiable impact to DreamWorks’ production pipelines and business infrastructure:
• A 20% performance increase was achieved using Lenovo Neptune™ liquid cooling, improving render speeds and enabling faster iteration cycles.
• A 25% performance increase of animation programs running on the ThinkStation™ P620s compared to previous workstations, leading to faster loading times and an overall better artist experience.
• With 98% utilization in its data center and 300 million compute hours for The Wild Robot, Lenovo infrastructure scaled to meet unprecedented creative demands.
“Based on our long-standing relationship and Lenovo’s consistent delivery excellence, expanding our collaboration was a natural next step,” said Kate Swanborg, SVP of Technology Communications and Strategic Alliances, DreamWorks Animation. “This deepens our collaboration and gives DreamWorks the flexibility and operational scale we need to fuel our business ambitions and deliver world-class filmmaking.”
“This expanded relationship underscores the vital role of advanced, scalable technologies and services in powering complex creative workflows and meeting the demands of modern content production,” added Ken Wong, Executive Vice President and President, Solutions and Services Group, Lenovo. “It highlights the strategic impact of a trusted technology partnership in delivering the performance, reliability, and innovation required to push the boundaries of what’s possible in filmmaking and what’s possible in business.”
Unified Innovation: Expanding the Lenovo–DreamWorks Technology Ecosystem
From strategy to 24/7 operations, Lenovo delivers more than just high-performance hardware -- it provides a services-first ecosystem that keeps DreamWorks’ technology teams focused. Lenovo’s scalable service model covers everything from day-to-day support to critical artist compute deployment, ensuring that enterprise environments like DreamWorks have the tools, agility, and responsiveness needed at every stage of production.
- ThinkStation™ and ThinkPad™ P Series Workstations – designed to deliver the performance and responsiveness required in any setting, including modern film production, making them ideal for artists, technical directors, and other professionals.
- ThinkSystem™ Servers and HPC Infrastructure – powering compute-intensive rendering and animation pipelines.
- NEW: TruScale™ Infrastructure as a Service – enabling DreamWorks to scale compute resources on demand while avoiding large capital expenditures. The offering supports the full ThinkSystem™ and ThinkAgile™ portfolio and is tailored to align infrastructure capacity with production timelines.
Lenovo TruScale™ allows DreamWorks to retain the control and security of on-premises infrastructure while benefiting from 24/7 proactive monitoring, managed services, and expert support. As part of its services portfolio, Lenovo also supports DreamWorks’ sustainability goals -- helping retire outdated systems and transition to more energy-efficient technologies.
And Infrastructure is only part of the story. DreamWorks depends on Lenovo’s Premier Support Plus for round-the-clock help, fast fixes, and minimal downtime. In a high-pressure creative environment, responsive support and expert planning are essential to reducing complexity and helping teams meet aggressive production goals.
Proven Performance: Technology That Moves at the Speed of Imagination
DreamWorks’ partnership with Lenovo is a story of creative ambition brought to life through cutting-edge technology. During its most technically demanding productions, DreamWorks relied on Lenovo’s high-performance computing (HPC) solution—featuring Neptune™ liquid cooling—to accelerate workflows and scale rendering. Neptune™ liquid cooling boosted core performance within the pre-existing data center space, enhancing both energy efficiency and system stability, and enabled the studio to do more with less. Just as critical was the ability to iterate in real time. With Lenovo’s infrastructure, artists could explore, refine, and bring complex digital environments to life with greater speed and precision.
Lenovo’s professional services have also enabled DreamWorks to scale quickly and smoothly. A HPC deployment expected to take a week was completed in just 1.5 days. From custom hardware integration to white-glove service and proactive support, every deployment is built for seamless execution and immediate production-readiness.
This robust technology and services foundation now supports a bold new slate of DreamWorks films, including The Bad Guys 2 (August 2025) and the newly announced Forgotten Island (September 2026). It will also play a central role in the creation of Shrek 5 (December 2026)—further demonstrating Lenovo’s impact on some of the studio’s most iconic and technically ambitious productions.
Looking ahead, Lenovo supports DreamWorks in streamlining complex operational and infrastructure processes as well as predictive analytics and intelligent workflows --powered by Lenovo’s AI-optimized infrastructure that includes workstations, data center systems, and TruScale services. While DreamWorks does not use AI in the generation of its imagery, the studio is researching its potential to increase production pipeline efficiency to further enable their artists to focus on their creativity. This integrated ecosystem would bridge individual creativity with end-to-end studio orchestration, helping DreamWorks move from concept to screen with greater speed, agility, and innovation.
“This extension of the Lenovo partnership is a key component of our technology strategy,” said Bill Ballew, CTO for DreamWorks Animation. “The Lenovo hardware solutions are incredibly powerful, and we are now looking forward to engaging with their AI teams to identify solutions that will optimize our compute infrastructure even further.”
“As production strategy evolves, the Lenovo-DreamWorks partnership serves as a blueprint for how enterprises can leverage integrated technology to scale intelligently and meet the demands of creative and operational excellence,” Wong added.
Learn More about How Lenovo Helps Turn Bold Ideas into Breakthrough Innovations
Discover what’s possible with Lenovo. Explore a full portfolio of workstations, data center solutions, and enterprise services designed to scale with creative and AI ambitions.
Unlock the Lenovo Hybrid AI Advantage to accelerate AI across edge, cloud, and on-prem environments. Rely onLenovo for expert support, from strategy to 24/7 operations. And start smart with AI Discover -- a guided consultation to identify use cases, assess readiness, and drive faster outcomes.
Visit here or connect with Lenovo experts at events worldwide.
LENOVO, THINKPAD, THINKSTATION, THINKSYSTEM, THINKAGILE and TRUSCALE are trademarks of Lenovo. ©2025 Lenovo Group Limited. All rights reserved.
About Lenovo
Lenovo is a US$69 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527158360/en/
Contacts
Zeno Group for Lenovo: lenovossg@zenogroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom